New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
May 11, 2023
98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published in Journal of Contemporary Brachytherapy
NASHUA, N.H., May 11, 2023 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling new long-term real-world research confirms Xoft Skin eBx is as safe and effective as Mohs surgery for the treatment of n... Continue reading
iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment
April 05, 2022
Multiple leading institutions leverage the versatility of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancers
NASHUA, N.H. – April 5, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that additional patients have been treated under the international multi-center GLIOX trial and cus... Continue reading
First Recurrent Glioblastoma Tumor is Treated with Xoft Brain IORT in the United States
December 14, 2021
Treatment marks initiation of international multicenter trial evaluating targeted radiation therapy and bevacizumab for the treatment of the most common and aggressive type of malignant brain tumor
Intriguing research supporting novel therapy approach recently published in peer-reviewed journal, Surgical Neurology International
NA... Continue reading
iCAD’s Xoft Brain IORT Demonstrates Significant Improvement in Overall Survival in Recurrent Glioblastoma According to Comparative Study
August 31, 2021
Patients treated with Xoft Brain IORT lived for a range of 4 to 54 months after treatment without recurrence, whereas patients in the control group had a recurrence within 2 to 10 months and lived for 2 to 22.5 months after treatment
NASHUA, N.H. – August 31, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, t... Continue reading
iCAD Announces Educational Webinar Featuring Leading Global Experts Discussing New Multidisciplinary Approach for Treating Brain Tumors, May 25
May 17, 2021
Company
sees positive momentum as research contributes to growing body of evidence
supporting Xoft intraoperative radiotherapy (IORT) technology for brain cancer
NASHUA, N.H. – May 17, 2021 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced a virtual roundtable discussion will feature leading
experts on brain cancer from around the globe sharing clinical updates on how... Continue reading
iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
December 29, 2020
International Multi-Center Study to Commence January 2021
University of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating
First European Patient Treated for Brain Metastasis with Xoft IORT System
NASHUA, N.H. – December 29, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the app... Continue reading
iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress
November 25, 2020
Growing Body of Evidence Supports Xoft Platform
Across Multiple Cancer Types
NASHUA, N.H. – November 25, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced that researchers from Miguel Servet University Hospital
in Zaragoza, Spain, will present new data from three clinical studies
supporting the efficacy of the expanded Xoft® Axxent® Electronic Brachytherapy (eBx... Continue reading
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
October 23, 2020
iCAD Showcasing Expanded Xoft Platform Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer Tumors
NASHUA, N.H. – October 23, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase the expanded platform for the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at the American Society for Radiation Oncology... Continue reading
New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma
October 19, 2020
New, Encouraging Results and Overall Patient Survival Numbers to be Presented at European Congress of Neurosurgery
NASHUA, N.H. – October 19, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that new, promising clinical results supporting the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the t... Continue reading
iCAD Responds to CMS’ Finalized Radiation Oncology Alternative Payment Model
September 20, 2020
IORT reimbursement unchanged; payment values for alternative, longer courses of radiation therapy reduced
NASHUA, N.H. – September 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional comments following the Centers for Medicare & Medicaid Services’ (CMS) publication of a new Innovation Cen... Continue reading
iCAD Appoints Jeffrey Sirek as Senior Vice President and General Manager of Xoft
July 20, 2020
NASHUA, N.H. – July 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Jeffrey Sirek was appointed as Senior Vice President and General Manager of Xoft.
“We are very pleased to add Mr. Sirek to our Company. He brings to the team a proven track record of high sales productivity, brand development, marketing success, an... Continue reading
iCAD Hosts Virtual Roundtable Event on Breast Cancer Surgery and Targeted Radiation During COVID-19
June 01, 2020
Leading breast cancer specialists to share best practices on leveraging the latest in cancer therapies to enhance patient care and minimize virus exposure
NASHUA, N.H. – June 1, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will host a free virtual roundtable event for clinicians, titled “The Impact of COVID-19 on Breast Cancer Surgery and Targeted Radiation Therapy,” on June 4, 2020 at 7 pm ET/4 pm... Continue reading
iCAD Presents Positive New Clinical Data for Xoft Brain IORT at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
May 13, 2020
Promising clinical research supports Xoft brain IORT as a viable treatment option for glioblastoma multiforme that may extend patients’ lives
Overall survival benefit reached statistical significance in the IORT group with tumors less than or equal to 2.5 cm3 (p<0.05)
NASHUA, N.H. – May 13, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solut... Continue reading
First Brain Tumor Treated with Xoft IORT in the United States
February 11, 2020
First U.S. procedure follows matched pair study indicating a promising improvement in overall survival
NASHUA, N.H. – February 11, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the first metastatic brain tumor was treated in the U.S. with intraoperative radiation therapy (IORT) using the Xoft® Axxe... Continue reading
iCAD Showcases Technology for Cancer “Discovery to Recovery” including ProFound AI Platform and Xoft System at Arab Health 2020 in Dubai
January 27, 2020
iCAD’s cancer detection and therapy technologies to be exhibited together for the first time in the Middle East, including the world’s first commercial deep-learning digital breast tomosynthesis solution and a single-fraction therapy option for early-stage breast cancer
NASHUA, N.H. – January 27, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutio... Continue reading
iCAD Exhibiting New Updates and Enhanced Xoft Platform at ASTRO Including Single-Fraction IORT Solution for the Treatment of Early-Stage Breast Cancer
September 16, 2019
Enhanced x-ray source technology and full suite of Xoft eBx applicators to be showcased, including those for emerging applications in prostate, brain, and rectal cancers
NASHUA, N.H. and CHICAGO – September 16, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the Company will showcase its latest advancements for the Xoft® Axxent® Electroni... Continue reading
iCAD Appoints R. Scott Areglado As Chief Financial Officer
May 06, 2019
NASHUA, N.H. -- May 6, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today appointed R. Scott Areglado as Chief Financial Officer. Mr. Areglado has been serving as interim Chief Financial Officer since December 2018, and previously held the role of Corporate Controller at iCAD since May 2011.
Continue reading
iCAD Wins Three-System Public Bid with Leading Cancer Organization in Spain, Expanding European Access to Innovative Cancer Treatments with the Xoft System
April 15, 2019
Two additional Spanish centers announce adoption of the Xoft System, totaling seven installations across four major regions in Spain
Internationally-recognized institutions strengthen portfolio of comprehensive cancer care solutions with iCAD’s state-of-the-art electronic brachytherapy technology
Continue reading
iCAD Appoints Stacey Stevens as President
March 28, 2019
Appointment establishes executive infrastructure to enhance strategic and operational momentum and capitalize on significant growth opportunities
Announcement follows pivotal FDA clearance and successful U.S. commercial launch of ProFound AI™ for digital breast tomosynthesis along... Continue reading
Long-Term Study of 1,000 Tumors Demonstrates Effectiveness of iCAD's Xoft Electronic Brachytherapy System for Early-Stage Breast Cancer Treatment
January 07, 2019
Prospective trial shows
that intraoperative radiation therapy (IORT) is a clinically effective, faster
and easier alternative to whole breast radiation therapy following
breast-conserving surgery for selected low-risk patients at a median follow-up
of 36 months
NASHUA, N.H., (January 7, 2019) – iCAD, Inc.
(NASDAQ: ICAD), a global medical technology leader providing innovative
cancer detection and therapy solutions, today announced the results of a
long-term study conducted at Hoag Memorial Hospital Pre... Continue reading
100 Comments